Evidence map›Paper›PMID 34107580›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells].

W N Yan, S B Li, H J Ma, D D Chen, J Wang, T Le, G Q Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. [MicroRNA 424-5p promotes the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting Kinesin family member 23].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

W N YanDepartment of General Surgery, Zhoushan Hospital, Zhoushan 316021, China.
S B LiDepartment of Infectious Disease, Zhoushan Hospital, Zhoushan 316021, China.
H J MaLaboratory of Cytobiology and Molecular Biology, Zhoushan Hospital, Zhoushan 316021, China.
D D ChenLaboratory of Cytobiology and Molecular Biology, Zhoushan Hospital, Zhoushan 316021, China.
J WangLaboratory of Cytobiology and Molecular Biology, Zhoushan Hospital, Zhoushan 316021, China.
T LeLaboratory of Cytobiology and Molecular Biology, Zhoushan Hospital, Zhoushan 316021, China.
G Q ZhangDepartment of General Surgery, Zhoushan Hospital, Zhoushan 316021, China.
Zhoushan Hospital · CN

Funding

National Natural Science Foundation of China 81502106Zhejiang Public Welfare Foundation LGF21H160020Zhoushan Medical and Health Science and Technology Project 2018A05
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansPhenotypePhenylurea CompoundsQuinolineslenvatinibMicroRNAsPhenylurea CompoundsQuinolinesChemosensitivityHepatocellular carcinomaLenvatinibMalignant phenotypemiR-23b

Identifiers

PMID34107580
PMCPMC12813894
OpenAlexW3196444665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.